Comparison of Neuropsychiatric Side Effects in an Observational Cohort of Efavirenz- and Protease Inhibitor-Treated Patients

REFERENCES

• Efavirenz (Sustiva®) prescribing information. Physicians' Desk Reference. 59th ed. Montvale, NJ: Medical Econom-ics Co., Inc.; 2005:1069–1075.
   Google Scholar
• Nevirapine (Viramune®) prescribing information. Physi-cians' Desk Reference. 59th ed. Montvale, NJ: Medical Economics Co., Inc.; 2005:1013–1019.
   Google Scholar
• Delavirdine (Rescriptorl prescribing information. Physi-cians' Desk Reference. 59th ed. Montvale, NJ: Medical Economics Co., Inc.; 2005:2529–2634.
   Google Scholar
• Pérez-Molina JA. Safety and tolerance of efavirenz in dif-ferent antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected pa-tients. HIV Clin Trials. 2002;3(4):279–286.
   PubMedGoogle Scholar
• Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emo-tional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 200229: 244–253.
   Google Scholar
• Zaccarelli M, Soldani F, Luzzi G, et al. CNS side effects as main risk factor for efavirenz (ER)) failure and transitory HIV-RNA elevation. Presented at: 9th Conference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, WA. Abstract 720–T.
   Google Scholar
• Guest JL, DeSilva KE, Flaherty TD, Le Fiore DB, Kimmerle DR, Rimland D. Tolerability of efavirenz in patients with a history of mental health disorder or substance abuse: data from HAVACS. Presented at: XIV International AIDS Con-ference; July 7–12, 2002; Barcelona, Spain. Abstract TuPeB4502.
   Google Scholar
• Peyriere H, Mauboussin JM, Rouanet I, Fabre J, Reynes J, Hillaire-Buys D. Management of sudden psychiatric disor-ders related to efavirenz. AIDS. 2001;15:1323–1324.
   PubMed Web of Science ®Google Scholar
• Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric ad-verse reactions associated with efavirenz. HIV Med. 2003;4:62–66.
   PubMedGoogle Scholar
• Blanch J, Martinez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001;27:336–343.
   PubMed Web of Science ®Google Scholar
• Treisman GJ, Kaolin Al. Neurologic and psychiatric compli-cations of antiretroviral agents. AIDS. 200216: 1201–1215.
   Google Scholar
• Clifford DB. ACTG A5097s impact of efavirenz on neurop-sychiatric performance, mood, and sleep behavior in HIV-positive individuals. Presented at: 2nd International AIDS Conference on HIV Pathogenesis; July 13–16, 2003; Paris, France. Abstract 54.
   Google Scholar
• Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmaco therapy. 2002;22:930–933.
   Web of Science ®Google Scholar
• Perry S, Bangsberg DR, Charlesbois ED, et al. Depressive symptoms predict mortality and HAART adherence. Pre-sented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16–19, 2001; Chi-cago, IL. Abstract 1–1721.
   Google Scholar
• Cook JA, Cohen MH, Burke J, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr. 2002;30:401–409.
   PubMed Web of Science ®Google Scholar
• Boly L, Cafaro V, Dyner T. A history of depressive symp-toms is predictive of an increased incidence of central nervous system (CNS) side effects in patients treated with efavirenz (EFV). Presented at: 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; October 28–31, 2001; Athens, Greece. Abstract 149.
   Google Scholar
• Starace F, Ammassari A, Trotta MP, et al., AdlCoNA Study Group, NeurolCoNA Study Group. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:S136–S139.
   PubMed Web of Science ®Google Scholar
• Tate D, Paul RH, Flanigan TP, et al. The impact of apathy and depression on quality of life in patients infected with HIV. AIDS Patient Care STDS. 2003;17:115–120.
   PubMed Web of Science ®Google Scholar
• Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonad-herence to antiretroviral medications in a sample of pa-tients with human immunodeficiency virus infection. Am J Med. 2003;114:573–580.
   PubMed Web of Science ®Google Scholar
• Asch SM, Kilbourne AM, Gifford AL, et al., for the HCSUS Consortium. Underdiagnosis of depression in HIV: who are we missing? J Gen Intern Med. 2003;18: 450–460.
   PubMed Web of Science ®Google Scholar
• Hawkins T, Grossman D, Haubrich R. CNS side effects of EFV may persist in patients thought to tolerate the drug. Presented at: XIII International AIDS Conference; July 9–14, 2000; Durban, South Africa. Abstract WePpB1377.
   Google Scholar
• Hawkins T, Geist C, Young B, et al. Efavirenz (EFV) induced CNS side effects persist for one year compared to pro-tease inhibitors (Pis). Presented at: 41st Interscience Con-ference on Antimicrobial Agents and Chemotherapy; Sep-tember 22–25,2001; Chicago, IL. Poster 1725.
   Google Scholar
• SCL-90 instrument screens patients for psychological dis-tress. Available at: http://www.pearsonassessments.com/tests/scI90r.htm. Accessed January 7,2005.
   Google Scholar
• Doherty G, Wong R, Seaton RA, et al. A retrospective analysis of neuropsychiatric side effects of efavirenz in Glasgow, UK. Presented at: 6th International Congress on Drug Therapy in HIV Infection; November 17–20, 2002; Glasgow, UK. Abstract 153.
   Google Scholar
• Juethner SN, Seyfried W, Aberg JA. Tolerance of efavirenz-induced central nervous system side effects in HIV-in-fected individuals with a history of substance abuse. HIV Clin Trials. 2003;4(3):145–149.
   PubMed Web of Science ®Google Scholar
• Nunez M, Gonzalez de Requena D, Gallego L, Jimenez-Nacherl, Soriano V, Gonzalez-Lahoz J. Impact of efavirenz plasma levels on development of severe central nervous system toxicity. Presented at: 41st Interscience Confer-ence on Antimicrobial Agents and Chemotherapy; Decem-ber 16–19, 2001; Chicago, Ill. Abstract 1–1724.
   Google Scholar
• Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS. 200115: 71–75.
   Google Scholar
• Fiske WD, Joshi AS, Labriola DF. An assessment of popu-lation pharmacokinetic parameters of efavirenz on nervous system symptoms and suppression of HIV RNA. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16–19,2001; Chicago, IL. Abstract 1727.
   Google Scholar
• Hartmann M, Rump A, Brust J, et al. Comparison of efavirenz and nevirapine in antiretroviral naive and pre-treated patients in a real world setting (NEEF Cohort). Presented at: XlVth International AIDS Conference; July 7–12, 2002; Barcelona, Spain. Abstract TuPeB4471.
   Google Scholar
• Negredo E, Cruz L, Paredes R, et al. Virological, immuno-logical, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis. 2002;34:504–510.
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, et al., for the 2NN Study Team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253–1263.
   PubMed Web of Science ®Google Scholar